Scarica l'app Stockscreener
0.00
100.00%
-8.61
Precedente Chiudi:
$8.61
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$391.22M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
0.00
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
646-885-8505
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
0.00 | 391.22M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Iniziato | Oppenheimer | Outperform |
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Will Y mAbs Therapeutics Inc. stock see insider buyingMarket Weekly Review & Daily Stock Trend Watchlist - newser.com
Is Y mAbs Therapeutics Inc. showing signs of accumulationIPO Watch & Short-Term Swing Trade Alerts - newser.com
Will Y mAbs Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trend Report & Short-Term Trading Opportunity Alerts - nchmf.gov.vn
What to do if you’re stuck in Y mAbs Therapeutics Inc.Fed Meeting & Real-Time Volume Analysis Alerts - newser.com
Can Y mAbs Therapeutics Inc. stock continue upward trendSell Signal & Safe Entry Point Identification - newser.com
Top chart patterns to watch in Y mAbs Therapeutics Inc.2025 Price Targets & Low Risk Entry Point Tips - newser.com
Is Y mAbs Therapeutics Inc. forming a reversal patternJuly 2025 Update & AI Driven Stock Reports - newser.com
Y mAbs Therapeutics Inc. stock trend forecastRate Cut & High Accuracy Trade Signal Alerts - newser.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Reduce” by Analysts - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
What drives Y mAbs Therapeutics Inc stock pricePrice-to-Book Ratio Updates & Start Your Free Trading Journey Today - earlytimes.in
Will Y mAbs Therapeutics Inc. rebound enough to break evenMarket Activity Report & AI Forecast for Swing Trade Picks - newser.com
Visual analytics tools that track Y mAbs Therapeutics Inc. performanceMarket Trend Review & Verified Technical Signals - newser.com
Will Y mAbs Therapeutics Inc. bounce back from current supportDip Buying & Daily Market Momentum Tracking - newser.com
Is Y mAbs Therapeutics Inc. stock bottoming outRisk Management & Safe Entry Zone Identification - newser.com
Trend analysis for Y mAbs Therapeutics Inc. this weekQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Is Y mAbs Therapeutics Inc. forming a bottoming baseJuly 2025 Setups & Step-by-Step Trade Execution Guides - newser.com
Relative strength of Y mAbs Therapeutics Inc. in sector analysisJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022 - MarketScreener
Is Y mAbs Therapeutics Inc a good long term investmentExit Strategy Tips & These Picks Are Just One Breakout Away - earlytimes.in
What analysts say about Y mAbs Therapeutics Inc stockResistance Breakout Alerts & Small Budget Capital Gain - earlytimes.in
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):